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The understanding of immunological interactions among the four dengue virus (DENV)
serotypes and their epidemiological implications is often hampered by the lack of individual-
level infection history. Using a statistical framework that infers full infection history, we
analyze a prospective pediatric cohort in Nicaragua to characterize how infection history
modulates the risks of DENV infection and subsequent clinical disease. After controlling for
age, one prior infection is associated with 54% lower, while two or more are associated with
91% higher, risk of a new infection, compared to DENV-naive children. Children >8 years old
have 55% and 120% higher risks of infection and subsequent disease, respectively, than their
younger peers. Among children with≥1 prior infection, intermediate antibody titers increase,
whereas high titers lower, the risk of subsequent infection, compared with undetectable
titers. Such complex dependency needs to be considered in the design of dengue vaccines
and vaccination strategies.
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As a leading mosquito-borne infectious agent, dengue virus(DENV) infects up to 390 million people annuallyworldwide, 25% of whom suffer from clinical disease.
Dengue epidemics have been expanding from tropical to sub-
tropical regions in recent decades and now put 3.9 billion people
at risk, partly fueled by urbanization and travel1–3. With four
antigenically distinct, but immunologically cross-reactive ser-
otypes (DENV-1–DENV-4), dengue has one of the most complex
transmission processes in human populations among all infec-
tious diseases. It is widely accepted that an infection with any
serotype offers long-term, if not life-long, immunity to disease
due to that serotype, but only short-term heterologous immunity
to other serotypes. In addition, a second infection is more likely
to present with severe symptoms such as dengue hemorrhagic
fever (DHF) or dengue shock syndrome (DSS) than a primary
infection4–6. However, how exactly previous infection history
modulates the risk of subsequent infection outcome is not entirely
clear, partly because of the difficulty in determining retro-
spectively the complete infection history of individuals using
current technology.
The Pediatric Dengue Cohort Study (PDCS) is an ongoing
longitudinal study conducted in Managua, Nicaragua7. In this
study, a prospective cohort of about 3800 children aged 2–9 were
initially enrolled in 2004. Enrollment continued in subsequent
years and the age span of the cohort was extended to 2–14 years.
Study participants are encouraged to seek medical care at a study
health center for all illnesses. Clinical specimens are collected
from children who meet the 1997 World Health Organization
(WHO) suspected dengue case definition or have undifferentiated
fever, and are evaluated using reverse transcriptase polymerase
chain reaction (RT-PCR), an in-house IgM capture enzyme-
linked immunosorbent assay (MAC-ELISA), and an inhibition
ELISA (iELISA) for acute DENV infection. To ascertain inap-
parent DENV infections, blood is drawn annually from each
participant. For the annual serum samples, the iELISA is used to
detect nonserotype-specific DENV infections. In addition, a pla-
que reduction neutralization test (PRNT, before 2007) and a
neutralization titration (NT) assay using reporter virus particles
are used to characterize serotype-specific neutralizing antibody
(Nab) responses on a non-random subset of iELISA-positive
samples, mostly from children with repeated infections based on
the iELISA.
Combining enhanced passive case detection and annual ser-
ology tests, this large cohort study provides one of the most
comprehensive data sets for investigating dengue transmission
and the effects of infection history on both the risk of infection
and the risk of developing dengue disease given infection in an
endemic country. We refer to the risk of disease given infection as
pathogenicity, as often seen in the epidemiological literature,
although pathogenicity also has the implication of severe disease
in other fields8. Specifically, the study provides clues to the fol-
lowing questions: (1) what are the serotype-specific annual
infection risks during the study years? and (2) what are the effects
of infection history and other host factors on the risk of infection
and the risk of developing symptoms given infection? The esti-
mation of infection risk differs from the estimation of disease
incidence as the latter is usually based on syndromic surveillance
data and does not account for inapparent infections and reporting
bias. Serotype-specific forces of infection (FoI) were estimated for
Iquitos, Peru from 1999 to 2010 by applying a smoothing splines
approach to several longitudinal serology cohorts9. However, the
estimation was done under the assumption that the infection
processes of the four serotypes were independent, and the FoIs
could have been underestimated through the exclusion of DENV
infections that were not serotyped. For the second question, it is
crucial to consider left-censoring of individual infection history
before study enrollment. An analysis based on the PDCS data but
ignoring left-censoring found that the average time from a pri-
mary inapparent infection to a second symptomatic infection was
longer than that from a primary inapparent infection to a second
inapparent infection, suggesting short-term cross-protection10.
However, the mean times between infections could be under-
estimated when the analysis is limited to the study observation
period.
Coupling the Nicaragua cohort data during 2004–2009 with
the national epidemiological surveillance data during 1995–2009
(epidemic year, e.g., 2009, and dengue season, e.g., 2009–2010, are
used exchangeably unless otherwise stated.), we develop a sta-
tistical framework to answer the above questions while account-
ing for the uncertainty in infection or serotype status during and
before the study. In addition, we also assess the role of pre-
dengue-season levels of binding antibodies and neutralizing
antibodies in the risk of infection and the risk of subsequent
disease given infection.
Results
Study participants. In total, 5086 individuals who contributed
definitive information (infection or no infection) for at least one
study year were included in the analyses of the Nicaraguan
cohort. Summary characteristics of the study participants, toge-
ther with laboratory test results are provided in Supplementary
Tables 1 and 2. The numbers of participants remained similar
over the study years (2004–2009). As participants gradually aged
within the cohort, the average age of the cohort increased. Based
on the partial laboratory confirmation data of the cohort, DENV-
1 and DENV-2 co-circulated in the 2004–2005 and
2005–2006 seasons, and then DENV-2 took the lead for the
2006–2007 and 2007–2008 seasons. DENV-3 was the major ser-
otype for the 2008–2009 and 2009–2010 seasons. The outbreaks
in the 2005–2006 and 2009–2010 seasons were relatively larger
than those in other seasons. The crude probability of symptoms
given infection, as represented by the proportion of RT-PCR-
confirmed infections among all detected infections, was much
higher in the 2009–2010 season, when DENV-3 was dominant,
than other seasons. A large proportion of infections was detected
solely by the iELISA each year (55–80%) without further
serotyping.
Annual risk of infection. Based on a Bayesian model fitted to
individual data from the cohort and surveillance data, we esti-
mated baseline annual probabilities of infection for each serotype
for all seasons from 1995 to 2009, where baseline refers to DENV-
naive children ≤ 8 years old in households with home ownership
and ownership of 1–2 electric fans (Fig. 1a; Supplementary
Table 3). Before the cohort was initiated in 2004, there were four
seasons dominated by DENV-3 (1995–1996, 1996–1997,
1997–1998 and 1998–1999), followed by three seasons of pri-
marily DENV-2 (1999–2000, 2000–2001 and 2001–2002) and two
seasons of DENV-1 (2002–2003 and 2003–2004). Five seasons
reached annual infection probabilities of nearly 10% or more,
covering all serotypes except for DENV-4, but all before the study
began. The highest infection probabilities were attained by
DENV-3 in season 1995–1996, 0.27 (95% credible interval [CI]:
0.23–0.31) and 1998–1999, 0.27 (95% CI: 0.24–0.31). The esti-
mates of baseline annual infection probabilities largely agree with
the trajectories of case numbers reported by the surveillance
system in Managua (Fig. 1b). The estimation of the infection
probabilities during the study period is mainly informed by the
study itself. For the years prior to 2004, the estimation is guided
not only by surveillance data via the relationship between infec-
tion probabilities and surveillance data during the study period
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but also by observed infection histories during the study period
via immunological constraints. This agreement assures us that the
information contained in the cohort data during the study period
is more or less consistent with that contained in the surveillance
counts. In addition, our estimates singled out DENV-2 as
imposing much higher risks of infection than other serotypes
during 2006–2007 and 2007–2008, which was not obvious in the
surveillance data. The relative magnitude of the estimated base-
line infection probability for DENV-3 in the 2009–2010 season
seems not to match the large outbreak size reported in surveil-
lance data. This is because the baseline probability of infection is
for dengue-naive children of 2–8 years old, while the surveillance
data reflect the synergy of serotype-specific probabilities of
infection, probabilities of disease given infection and all relevant
risk factors, e.g., age and infection history. Population growth in
Managua during 1995–2009 might have also contributed; that is,
the number of DENV-3 cases captured by surveillance in 2009
could be higher than those in the 1990s because of a larger sus-
ceptible population, although the risk of infection did not
increase.
Factors affecting risk of infection. With individual-level infec-
tion history sampled via Markov chain Monte Carlo, we were able
to assess the association of infection risk with demographics,
infection history and living conditions (Fig. 2; Supplementary
Table 4, Scenario 2). Compared to children ≤8 years old, older
children had a higher risk of infection, with an odds ratio (OR) of
1.55 (95% CI: 1.39–1.74). After controlling for age, having one
previous infection significantly reduced the risk of infection with
an OR of 0.46 (95% CI: 0.34–0.60), whereas having two or more
prior infections increased the risk of infection with an OR of 1.91
(95% CI: 1.34–2.64), both compared to the DENV-naive group.
Among individuals infected once previously, the risk of a sec-
ondary infection 3 or more years after the primary infection,
compared to 1 year after, was moderately increased with an OR of
1.47 (95% CI: 1.10–2.06), suggesting the potential role of short-
term cross-immunity. In contrast, among individuals infected
twice or more, the risk of infection exhibited a decreasing ten-
dency over time, with an OR of 0.66 (95% CI: 0.44–1.02) 3 or
more years after the most recent infection relative to 1 year after.
Indeed, if the risks at 1, 2, and ≥3 years postinfection are com-
pared directly with the DENV-naïve group, one can see a clear
trend of decay over time for both the protective effect of the
primary infection and the risk-boosting effect of secondary
infections: the respective ORs for 1, 2, and ≥3 years are 0.46, 0.52,
and 0.68 for the former and 1.91, 1.45, and 1.26 for the latter
(Supplementary Notes, Section 2.2). Simple correlation statistics
showed that house ownership and possession of electric fans were
negatively associated with infection (Supplementary Table 5).
Home ownership lowered the risk of infection by about 20%, with
an OR of 0.81 (95% CI: 0.71–0.93). Interestingly, having 1–4
electric fans in the house reduced the risk of infection by about
32%, and having 5 or more fans reduced the risk by about 45%,
both compared to no fan at all and with statistical significance.
Factors affecting probability of disease given infection. The
probabilities of disease given infection varied substantially by
serotype. DENV-3 was the most pathogenic serotype, with 24%
(95% CI: 19–30%) infections being symptomatic (Fig. 3; Sup-
plementary Table 6, Scenario 2). DENV-1 and DENV-2 were
similar in their pathogenicity, with the probabilities of disease
estimated as 10% (95% CI: 7–13%) and 13% (95% CI: 11–16%),
respectively. DENV-4 was the least pathogenic, causing clinical
disease in only 2% (95% CI: 0–6%) of infections. Compared to
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Fig. 1 Estimated probabilities of infection and reported numbers of cases by serotype and year. Serotypes are colored in black for DENV-1, red for DENV-2,
blue for DENV-3, and green for DENV-4. a The model-predicted serotype-specific probabilities of infection. Points and vertical bars indicate posterior
medians and 95% credible intervals. b The number of surveillance-reported cases in Managua, Nicaragua, from 1995 to 2009. The year is defined as July of
a year to June of the next year, to be consistent with the dengue season in the study region. Serotype-specific surveillance counts were imputed using
information obtained from PAHO and literature (Supplementary Methods). Source data are provided as a Source Data file
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children ≤8 years old, older children had twice the odds of disease
given infection, with an OR of 2.20 (95% CI: 1.46–3.37). We
assessed the association between infection history and the prob-
ability of disease given infection stratified by age. Among children
>8 years old, the OR of disease given infection in year 2 after the
most recent infection was 0.19 (95% CI: 0.03–0.77), compared to
year 1. We found no association between the number of prior
infections and the probability of disease given infection.
Effects of preseason antibody levels. We explored the relation-
ship between the preseason total binding antibody levels mea-
sured by the nonserotype-specific iELISA and the probabilities of
secondary DENV infection, symptomatic secondary infection,
and disease given secondary infection (Supplementary Table 7).
This analysis was restricted to study person-years with evidence
for one or more prior infections. Compared to those with
undetectable titers (<10), low-to-medium levels of iELISA titers
were associated with increased risk of secondary infection, with
ORs estimated as 3.13 (95% CI: 2.16–4.52) for titers 10–20 and
1.83 (95% CI: 1.28–2.62) for titers 21–80. High levels of antibody
titers (>1280) were associated with substantially lower risk of
secondary infection, with an estimated OR of 0.38 (95% CI:
0.24–0.60). The risk of symptomatic secondary infection was
more than twofold for low-to-medium levels of iELISA titers
(10–80) as compared to undetectable, but the differences did not
attain statistical significance. For the risk of disease given sec-
ondary infection, the highest level (>1280) seemed to be asso-
ciated with elevated pathogenicity compared to undetectable, with
an estimated OR of 3.60 (95% CI: 0.99–13.09). We found no
relationship between the risk of disease given secondary infection
and Nabs measured by PRNT or NT assays.
Distribution of time intervals between infections. The posterior
distributions of the time intervals between two consecutive
inapparent infections and from an inapparent infection to a
symptomatic infection are compared (Fig. 4). When only the
infection pairs that occurred within the study period (2004–2009)
were used for estimation, we estimated the posterior mean time
interval between two inapparent infections to be 2.11 (95% CI:
1.90–2.31) years, slightly shorter than 2.34 (95% CI: 1.97–2.71)
years from an inapparent infection to a symptomatic infection.
Without such restriction, i.e., using observed and imputed
infections during 1995–2009, the posterior mean of time intervals
between two inapparent infections, 4.56 (95% CI: 4.26–4.87)
years, remained shorter than that from an inapparent infection to
a symptomatic infection, 5.02 (95% CI: 4.32–5.71) years, but both
are longer than the estimates restricted to the study period only.
This underestimation of the time interval between infections
when data are restricted to a short period was seen in the
simulation study as well.
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Fig. 2 Estimated effects of risk factors for DENV infection. Associations with the risk of DENV infection are shown as posterior medians (points) and 95%
credible intervals (horizontal bars) of odds ratios for age group, number (#) of prior infections, years since most recent infection, home ownership and
number of electric fans. The reference (Ref) group is children aged 2–8 years, without any prior infection, with no household ownership and no fan in their
household. Source data are provided as a Source Data file
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Sensitivity analyses. As serotype-specific surveillance data are
missing for some years, we conducted sensitivity analyses by
changing the proportions of nondominant serotypes in the con-
struction of serotype-specific surveillance data (Supplementary
Methods, Section 1.1; Supplementary Figure 1). The proportions
of nondominant serotypes are assumed to be 10% in the primary
analysis (scenario 2), and 5% (scenario 1) and 15% (scenario 3) in
the sensitivity analyses. The estimated annual probabilities of
infection, probabilities of disease given infection, and effects of
risk factors in the sensitivity analyses are similar to our primary
results (Supplementary Figure 2; Supplementary Tables 4 and 6).
Model adequacy and validation. By simulating epidemics in the
pediatric cohort using the primary model and posterior samples
of the parameters, we compared the model-predicted non-
serotype-specific annual attack rates to the observed ones (Sup-
plementary Methods, Section 1.7). The similarity between the
model-predicted and observed annual attack rates suggests a
decent goodness-of-fit of the model to the cohort data (Supple-
mentary Table 9). We also used a conditional expectation
approach to test the null hypothesis that the model-predicted
infection numbers conditioning on the past and observed infec-
tion numbers for each study year were similar (Supplementary
Methods, Section 1.7; Supplementary Table 10). The p value of
this Chi-squared test was >0.99 for comparison by year and 0.36
if comparison is further stratified by age group, suggesting that
the model fits the data satisfactorily.
We further validated our method by repeatedly simulating and
analyzing epidemics in a pseudocohort (Supplementary Methods,
Section 1.4). Across 100 simulated epidemics, the mean estimates
of the parameters were mostly close to, and the interquantile
ranges (between 2.5% and 97.5% quantiles of the estimates) all
contain, their true values (Supplementary Figure 3), indicating the
statistical validity of our method in general. These results together
ensure the reliability of our estimates on the annual risks of
infection during the study period as well as before the enrollment
of the cohort (before 2004).
Discussion
Understanding the dynamics of DENV infection and risk modi-
fiers requires knowledge about individual-level infection history,
which is usually not fully observed even in pediatric cohort stu-
dies. To address this challenge, we developed a statistical
approach that combines individual-level data from prospective
serological cohorts with surveillance data, which facilitates joint
inference of missing or left-censored infection history and epi-
demiological parameters. Using this approach, we estimated
serotype-specific annual risk of infection for children in Managua,
Nicaragua, from 1995 to 2009. In addition, we assessed risk
modifiers for both infection and pathogenicity. In comparison
with previous studies that modeled unobserved infections of
dengue or influenza, our approach differs in that the complete
infection history since birth is sampled for each individual and
the sampling is informed by surveillance data11–13. We did not
model antibody titers dynamics directly, as the serum samples
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Fig. 3 Estimated probabilities of disease given infection and effects of risk factors. Points and vertical bars indicate posterior medians and 95% credible
intervals. a Serotype-specific probability of disease given infection. b Association of the risk of disease given infection with serostatus at entry, age group,
and years since most recent infection. The reference group is children aged 2–8 years, without prior infection. Source data are provided as a Source Data file
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09193-y ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:1246 | https://doi.org/10.1038/s41467-019-09193-y | www.nature.com/naturecommunications 5
were collected at 1-year intervals, in comparison to quarterly
collection in Salje et al.11, and the quantity of serotype-specific
antibody titers is limited.
The dramatic fluctuating pattern in the annual probabilities of
infection for most DENV serotypes has been previously docu-
mented, as many time-varying factors can influence the viral
competition for susceptible individuals, including the herd
immunity profile, distribution of vectors, climatic conditions, and
chance itself2,9. Age plays a key role in the risk of DENV infec-
tion, especially among children. Older children are more active in
exposure-related behaviors, have more body surface area, produce
more carbon dioxide, and are hence more likely to be infected as
compared to their younger peers; however, their actual risk is
complicated by the fact that they have had more prior infections
and are more likely protected by cross-immunity4,14–16. Without
controlling for infection history, a previous study found no dif-
ference in the probability of infection between older and younger
children in the PDCS cohort4. After controlling for infection
history, we found that older children (>8 years of age) had a
higher risk of infection than younger ones, a difference that might
be partially attributable to the lower mobility of the latter17,18.
We found that one prior infection was protective against but
two or more were a risk factor for another DENV infection, and
that both effects decayed over time. Cross-immunity may account
for the protective effect of a single prior infection19. The elevated
risk associated with two or more prior infections compared to
that among DENV-naive population has been observed before,
e.g., in a longitudinal study in Iquitos, Peru, and could be con-
tributed by individuals who were much more exposed to the
vectors (mainly Aedes aegypti) or more susceptible to DENV and
thus repeatedly infected20,21. Heterogeneity in susceptibility could
be attributed to genetic variation or weaker immune response to
prior infections22–24.
It has long been speculated that a primary DENV infection
confers short-term cross-immunity against a secondary sympto-
matic infection that wanes in less than two years10,19,25. Less was
known about the duration of cross-immunity against a secondary
infection. We found that after the primary infection, the risk of a
new infection during the second year was similar to that during
the first year. In the third year and onwards, however, the risk was
increased by about 47% (Supplementary Table 4). Increasing risk
of infection with time since primary infection has not been
controlled for in previous analyses of waning cross-protection
against symptomatic as compared to inapparent infection and
this may affect estimates of waning cross-protective immunity.
After two or more infections, although the risk of a new infection
was higher during the first year compared to after a single or no
prior infection, there appeared to be a trend of declining risk over
the subsequent years. This declining trend could be related to
behavioral changes that led to decreased exposure. It may also
imply that the cross-immunity after two or more infections
becomes more sustained.
Our results showed that home ownership and the ownership of
electric fans were associated with lower risk of infection. Previous
studies noted that proxies of low social economic status, such as
the use of pit latrines and the lack of air-conditioning, were
predictive of higher risks of dengue transmission26,27. In general,
improved living conditions associated with a higher socio-
economic status may reduce exposure to mosquitoes. The pro-
tective effect of ownership of electric fans is most likely because
mosquitoes bite less when fans are blowing, and it could have
implications for dengue prevention in resource-limited settings
where air-conditioning is not affordable. Even after controlling
for these risk-predictive social economic variables, children with
two or more prior infections were still identified with a high risk
of infection, further indicating the existence of an excessively
exposed group.
We found that DENV-3 was the most pathogenic, whereas
DENV-4 was the least, among all four serotypes, similar to pro-
spective studies in Thailand1,11,28. Previous studies in Nicaragua
have found DENV-2 to be associated with severe clinical mani-
festations29–31. A pooled analysis of data from multiple countries
identified DENV-1 as the most pathogenic and DENV-2 the
least32. Together, this suggests the possibility of spatial and
temporal heterogeneity in the pathogenicity of DENVs and its
determinants. Older children in our study were more than twice
as likely to develop disease upon infection, controlling for the
number of prior infections, which resembles observations in
southern Vietnam33. A study among school children in Kam-
phaeng Phet (KPP), Thailand also suggested seven-year olds
experienced a lower symptomatic to inapparent ratio than 8–13
years old children, although that study did not include younger
children1,28.
While secondary infection is a known risk factor for severe
manifestations such as DHF, our results suggest that the overall
probability of symptomatic disease given infection was invariant
to the number of prior infections, regardless of age group (Sup-
plementary Table 6), which is consistent with a previous study on
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Fig. 4 Posterior distribution of the time interval between consecutive infections. Results are colored in red for the time between inapparent infections and in
blue for the time between an inapparent infection and a symptomatic infection. a Estimation is restricted to infections that occurred during the study.
b Estimation is based on the proposed method combining the study period and the years before study entry. Source data are provided as a Source Data file
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the PDCS cohort10. On the other hand, secondary infections were
found more likely to be symptomatic than primary ones in both
the multicountry pooled analysis and the study in southern
Vietnam32,33. However, such difference was not seen in Nicar-
agua studies included in the pooled analysis, nor was it observed
for most serotypes except for DENV-132. The gap between these
analyses and ours indicates that the role of prior infections in the
risk of disease given infection may vary geographically. We
conducted an additional analysis by stratifying serotype-specific
probabilities of disease given infection by the number of prior
infections (0 vs. ≥1) and found that, for DENV-2, this probability
of disease for secondary infections doubled that for primary
infections (Supplementary Table 11). The DENV-2 epidemics
during the study period were preceded by DENV-1 epidemics
during 2002–2004 in Managua (Fig. 1), which could be related to
our finding as increased pathogenicity of DENV-2 in terms of
severe disease following previous infection with DENV-1 has
been noticed before31,34.
Among children >8 years, there was a strong protection against
disease given infection in year 2, in comparison to year 1, after the
most recent infection, which extended to year 3 and beyond with
diminishing strength (Fig. 3; Supplementary Table 6). In contrast,
the probability of disease given infection peaked in year two
among younger children, though not significantly higher than the
years before and after. The same patterns can also be clearly seen
in the crude estimates for the probabilities (Supplementary
Table 12). The geometric mean preseason iELISA titers among
children >8 years with new infections at 1, 2, and 3 years after the
most recent infection were 153, 78, and 59, respectively, vs. 63,
112, and 43 among younger children. There appears to be a
positive correlation between the probability of disease given
infection and the mean preseason titers. Similar patterns for the
effect of years since the most recent infection on the probability of
disease given infection are seen if we stratify the effect by the
number of prior infections rather than age group (Supplementary
Table 13), which is not surprising as older children tended to
have more prior infections. These results also suggest patho-
genicity may not be irrelevant to the number of prior infections if
controlling for the year since the most recent infection, e.g., the
ratio between the probability of disease given infection in year 1
after a secondary infection and that after a primary infection is
1.97/0.75= 2.63, though not statistically significant.
By deconvoluting the risk of dengue disease into the risk of
infection and the risk of disease given infection, we found that the
preseason antibody level acted differently on infection and disease
given infection. Low-to-medium antibody levels were associated
with increased risk of secondary infection, whereas high levels
were protective. Although antibody-dependent enhancement
(ADE) of severe disease among secondary DENV infection is
well-known, this antibody-dependent risk of secondary infection
has not been previously reported. Based on the same cohort but a
longer observation period, Katzelnick et al.35 showed a clear
pattern of ADE for DENV infections with severe disease out-
comes, but not for the risk of symptomatic DENV infection.
Consistent with this, a recent analysis of the Thailand-KPP cohort
during 1998–2003 by Salje et al.11 showed an ADE pattern for
hospitalization and DHF but not for symptomatic DENV infec-
tion or DENV infection. In contrast to these studies, our analysis
was restricted to secondary infections. Our study did not show a
statistically significant ADE pattern for the risk of symptomatic
DENV infection either, but among those with at least one prior
infection, iELISA titers ≤80 were associated with nearly twice risk
of symptomatic DENV infection as compared to undetectable
and higher titers (Supplementary Table 7). Several factors may
have contributed to the difference in the association of risk of
DENV infection with pre-infection titer between the PDCS
cohort and the Thailand-KPP cohort, e.g., differences in circu-
lating DENV genotypes, exposure frequency, and assays for
measuring antibody titers (Haemagglutination inhibition was the
main assay in the Thai study). On the other hand, both Salje et al.
and our study found that high titers were protective against
secondary infections (inapparent and symptomatic).
Our analysis found no clear association between antibody
levels and the probability of dengue disease given infection,
consistent with the recent analysis of the Thailand-KPP study11.
Interestingly, both analyses implied some degree of enhancement
of disease given infection associated with very high antibody
levels (Supplementary Table 7; Extended Data Fig. 6 of Salje
et al.). For our study, one explanation is that when the preseason
titer was already high, inapparent infections might not be able to
induce a fourfold increase in iELISA titer and might have been
under-detected, which in turn would artificially raise the pro-
portion of disease among all infections. As a sensitivity analysis,
we relaxed the definition of infection such that a twofold increase
in iELISA also implies infection when the preseason titer was
≥1280. The pathogenicity-enhancing effect of high titers indeed
disappeared (Supplementary Table 8). As expected, the protective
effect of high titers against infection also vanished. An alternative
plausible explanation is that, as a high preseason antibody level is
protective against infection, a high viral load may be necessary for
a successful infection and thus result in higher pathogenicity. This
effect, if true, could partially account for the observation men-
tioned above that the probability of disease given infection peaked
in year 1 since the most recent infection among children >8 years
old but in year 2 among younger children (Supplementary
Table 6) and the peak pathogenicity seemed to be associated with
a higher mean preseason iELISA titer.
A few limitations should be considered for proper interpreta-
tion of our results. First, the serotype-specific antibody detection
methods, PRNT and NT, were only available for a small subset of
serum samples in this study36,37. As a result, most inapparent
infections were captured by iELISA, which is nonserotype-
specific. Second, antibody levels, especially serotype-specific ones,
were not directly modeled due to their limited availability despite
their importance in the risk of infection and disease
severity11,23,35. Therefore, we explored the impact of
nonserotype-specific antibody levels by correlating them with
model outputs, and the uncertainty of model outputs was
accounted for (Supplementary Methods, Section 1.6). Moreover,
with most infection times known only up to the year for an
observation period of 6 years, the model does not capture var-
iations of the risks at finer time scales or in the long run. Should
more years of data become available or serological specimens be
sampled more frequently in the future, a parametric curve can be
fitted for the effect of the time since most recent infection to
better characterize the waning of cross-immunity. Finally, while
epidemiological surveillance data greatly improve inference on
infection history, the analytic results could be sensitive to the
accuracy of such data especially for the period not covered by the
cohort data. For example, the estimated infection probabilities for
DENV-1 in 1995 and for DENV-4 in 2000 vary substantially with
different assumptions on how surveillance-reported cases are
allocated to serotypes (Supplementary Figure 2).
In conclusion, our analytic framework offers insights on how
the risk of DENV infection and the risk of disease given infection
are related to the infection history at the individual level, and is
readily generalizable to other complex infectious diseases. While
prospective cohorts provide the most valuable information about
dengue transmission, we emphasize the necessity to improve the
coverage and quality of general surveillance systems in dengue-
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endemic countries sponsored by governments or nongovern-
mental organizations. If future dengue vaccine trials are supple-
mented with high-quality surveillance data, our method could be
used to reliably assess the dependency of vaccine safety and
efficacy on individual-level infection history.
Methods
Study design. The PDCS study is an ongoing prospective pediatric cohort study
conducted in Managua, Nicaragua4,7,9. Recruitments were initiated in August 2004
by home visits as well as at the study health center, Health Center Sócrates Flores
Vivas (HCSFV). Children from 2 to 9 years old were invited to join the study.
During the first 3 years, participating children remained eligible until 12 years old.
This age limit for eligibility was extended to 14 years starting year 4. Participants
are encouraged to seek free medical services for all illnesses, in particular for febrile
illnesses, at HCSFV 24 h a day all year round. Acute and convalescent samples are
collected from individuals who meet the 1997 WHO criteria for suspected dengue
or have undifferentiated fever. An annual serum sample is also collected from each
study participant in each July before the dengue season started. We included in our
analysis the data from the first six years of study (August 2004 to July 2010).
Surveillance data. Epidemiological surveillance data of reported dengue cases
were obtained from the Pan American Health Organization (PAHO, http://www.
paho.org). Proportions of the national surveillance cases accounted for by Managua
were obtained from Nicaraguan Ministry of Health (Supplementary Methods,
Section 1.1).
Definition of inapparent and symptomatic infections. RT-PCR, MAC-ELISA,
and iELISA were used to confirm and serotype clinical cases for acute DENV
infection7. All annual samples were evaluated using the iELISA. A subset of
individuals with iELISA-positive samples was selected, whose samples further
underwent PRNT or a flow cytometry-based NT to measure serotype-specific
Nabs. To determine infection and the infecting serotype, we assume the following
priority ranking of the four diagnostic methods: RT-PCR, NT, PRNT, and iELISA.
For samples tested with only iELISA, the serotype is unknown. Symptomatic
infection was defined as dengue-like symptoms with either detection of DENV
RNA by RT-PCR, detection of seroconversion by MAC-ELISA or iELISA, or
≥fourfold rise in iELISA titers between acute and convalescent sera. Paired annual
sera with seroconversion or a ≥fourfold increase in antibody titers measured by NT
or iELISA, or an increase in percent inhibition measured by single-dilution PRNT
from <65 to ≥70, with difference greater than or equal to 20, were considered
evidence of inapparent infection for individuals without DENV-confirmed febrile
episodes. For the 351 symptomatic infections detected in our study period, 138
(39.3%) of them were hospitalized4.
Ethics. The study was approved by the Institutional Review Boards (IRBs) at the
University of California, Berkeley, the Nicaraguan Ministry of Health, and the
International Vaccine Initiative. Written consent was obtained from a parent or
guardian, or if the guardian was illiterate, the consent form was read aloud in the
presence of a witness and the guardian’s thumbprint was obtained in lieu of a
signature, as approved by the IRBs. Verbal assent was obtained from all children
aged six years and older.
Statistical model. To estimate serotype-specific annual risk of infection and the
effects of infection history on the risk of infection and the risk of disease given
infection, we developed a Bayesian modeling framework that integrates the pro-
spective cohort and the surveillance data in the study area (Supplementary
Methods, Section 1.2). The proposed model has three components that model the
infection outcomes, the disease outcomes given infection, and the probabilistic
linkage between the total infection numbers in the study cohort and the surveil-
lance data. For the infection component, annual infection probabilities for each
serotype were adjusted for demographic variables and infection history via logistic
regressions, where the infection outcome was determined assuming competing
risks among the four serotypes (Supplementary Methods, Section 1.2.2). Infection
history was proxied by number of prior infections and number of years since the
most recent infection. To adjust for heterogeneity in individual level exposure,
social economic variables including parent education level, floor type of the house,
and ownership of house, car, television sets, electric fans, refrigerators, and animals
were screened by Spearman correlation with infection incidence during the study
period (Supplementary Methods, Section 1.5). Variables exhibiting strong corre-
lation were included in the model. Similarly, the probabilities of developing disease
(symptoms) given infection were also adjusted for demographics and infection
history via logistic regressions (Supplementary Methods, Section 1.2.3). To inform
the imputation of the infection history before 2004, we assumed there was a
common fraction of total DENV infections captured by the syndromic surveillance
system across years. The linkage component scales up the yearly number of
infections of each serotype in the cohort to the expected number of reported cases
in Managua and assigns a Poisson distribution to the actual number of reported
cases (Supplementary Methods, Section 1.2.4). A model schematic is shown in
Supplementary Figure 4.
Statistical inference. Joint statistical inference on parameters of interest, missing
infection histories, and missing socioeconomic covariates was implemented with
the data-augmented Markov chain Monte Carlo (MCMC) techniques38. In each
MCMC step, we first updated the model parameters using the random walk
Metropolis–Hasting algorithm, and then we updated the infection history for each
individual by exhausting all possible sequences of infections (pathways) that were
compatible with the observed data. Compatibility with observed data was verified
by the following immunological assumptions: (1) each individual could be infected
by at most one serotype in each year; and (2) each individual could be infected by a
given serotype at most once. The relative likelihoods of all data-compatible path-
ways were then computed and served as the weights for sampling the missing
infection history. Lastly, we updated the missing values in categorical covariates by
considering all possible combinations in these values, similar to the imputation of
infection history (Supplementary Methods, Section 1.3). This approach is the
Bayesian analogue of the pathway expectation-maximization algorithm we devel-
oped for vaccine studies16,39.
Distribution of time interval between infections. From the MCMC samples of
unobserved infection and disease outcomes, we derived and compared the pos-
terior distribution of the time from an inapparent infection to a symptomatic
infection to that between two inapparent infections.
Effects of preseason antibody on risk of infection or disease. We explored the
effects of preseason antibody levels on the risks of infection, dengue disease
(symptomatic infection), and disease given infection using regression models. All
regressions were adjusted for age group (2–8 and >8), number of prior infection
(1 and >1) and study year. We examined three types of preseason antibody levels:
homologous and heterologous Nabs measured by PRNT or NT and the total
DENV-specific binding antibodies measured by iELISA. For Nabs, only their
effects on the risk of disease given infection were examined. As pathogenic out-
comes of secondary infections tend to be more severe, this exploratory analysis was
restricted to the study follow-up period after primary infections. The technical
details including how to account for uncertainty from both the regression and the
MCMC sampling are provided in Supplementary Methods, Section 1.6.
Model adequacy and validation. We evaluated the goodness-of-fit of the model to
the data during the study period by two approaches (Supplementary Methods, Section
1.7). We first prospectively simulated dengue epidemics in the PDCS using a subset of
the posterior samples of the parameters and compared the simulated nonserotype-
specific annual attack rates to the observed ones. We then formally tested the dif-
ference between observed nonserotype-specific annual infection numbers and model-
predicted frequencies conditioning on the past. To ensure the validity and general-
izability of our model, we performed a formal simulation study. We simulated 100
dengue epidemics in a pseudocohort of 2000 individuals. For simplicity, all indivi-
duals were set to enter the study at the same time with ages at enrollment randomly
assigned to 2–5 years, and to be followed for six years. The infection history before
study entry for the whole population, as well as the serotype information for 60% of
infections during the study period, were set to be missing, similar to the PDCS data.
The cohort was assumed to be contained in a larger population for which surveillance
counts by serotype were available to inform the overall risk of infection before study
entry. We applied our algorithm to estimate the model parameters for each of the
simulated epidemics.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Code availability. Computer code (in R and C languages) for conducting simu-
lations and data analysis can be downloaded from https://github.com/timktsang/
Nicaragua_dengue.
Data availability
Data-sharing requests may be directed to the UC Berkeley Center for the Proteciton of
Human Subjects at ophs@berkeley.edu, subject to IRB approval at UC Berkeley.
Summary data presented in the figures are included in the Source Data file as part of
the Supplementary Information. These summary data, together with the study protocol,
can also be downloaded from https://github.com/timktsang/Nicaragua_dengue.
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